14,514 results match your criteria Aids[Journal]


Opioid agonist treatment improves progression through the HIV cascade of care among people living with HIV who use unregulated opioids.

AIDS 2022 May 24. Epub 2022 May 24.

British Columbia Centre on Substance Use.

Objectives: Opioid agonist treatment (OAT) has been shown to improve certain HIV-related treatment measures among people with HIV (PHIV) with opioid use disorder (OUD). However, there is limited data on the impacts of OAT along the whole HIV cascade of care.

Design And Methods: Using data from an ongoing cohort of PHIV who use drugs in Vancouver, Canada, we used cumulative link mixed-effects models to estimate the independent effect of OAT on achieving progressive steps in the HIV cascade among participants using unregulated opioids daily, after adjusting for confounders. Read More

View Article and Full-Text PDF

Anti-CD4 autoantibodies in immunological non-responder people living with HIV: Cause of CD4+ T-cell depletion?

AIDS 2022 May 24. Epub 2022 May 24.

Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, CSIC.

Objective: We aimed to evaluate the anti-CD4 IgG role in the poor immune recovery of immunological nonresponder people with HIV (INR).

Design: INR display low CD4+ T-cell increase despite long-term undetectable viremia. Among other factors, autologous anti-CD4 IgG-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells has been proposed to cause CD4+ T-cell depletion. Read More

View Article and Full-Text PDF

Isoniazid preventive therapy and TB transcriptional signatures in people with HIV.

AIDS 2022 May 24. Epub 2022 May 24.

Department of Medicine, University of Washington, Seattle, WA.

Objectives: To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV.

Design: Cross-sectional study.

Methods: We enrolled adults living with HIV who were IPT-naive or had completed IPT more than 6 months prior at HIV care clinics in western Kenya. Read More

View Article and Full-Text PDF

Thrombotic thrombocytopenic purpura (TTP) in Human immunodeficiency virus (HIV) infected patients: New twists on an old disease.

AIDS 2022 May 24. Epub 2022 May 24.

Department of Immunology, School of Health Sciences, University of the Witwatersrand (Wits), National Health Laboratory Service (NHLS), Johannesburg, South Africa.

Objective: Investigate the presence of inflammation, endothelial dysfunction and complement activation in patients with HIV-associated thrombotic thrombocytopenic purpura (HIV-TTP) to support the hypothesis that these processes probably contribute to the development of this thrombotic microangiopathy.

Design: A prospective, investigational cohort study of 35 consecutive patients diagnosed with HIV-associated TTP presenting to three academic, tertiary care hospitals in Johannesburg, South Africa over 2 years.

Methods: The patients with HIV-TTP received therapeutic plasma therapy and supportive treatment. Read More

View Article and Full-Text PDF

Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multi-country longitudinal cohort analysis.

AIDS 2022 May 24. Epub 2022 May 24.

Amsterdam Institute for Global Health and Development, and Department of Global Health, Amsterdam UMC, University of Amsterdam.

Objective: In a multicountry prospective cohort of persons with HIV from six countries between 2007 and 2015, we evaluated long-term outcomes of first-line non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy (ART), and risk factors for loss-to-follow-up, mortality, virological failure, and incomplete CD4+ T-cell recovery.

Methods: We calculated cumulative incidence of lost-to-follow-up, death, virological failure (VL ≥ 1000 cps/ml) and incomplete CD4+ T-cell recovery (<500 cells/μl) at successive years, using Kaplan-Meier and Cox regression.

Results: Of 2735 participants, 58. Read More

View Article and Full-Text PDF

Incident depression among Medicare beneficiaries with disabilities and HIV.

AIDS 2022 May 24. Epub 2022 May 24.

Department of Preventive Medicine and Population Health.

Objective: Despite disproportionally high prevalence of HIV and depression in persons with disabilities, no data have been published on the incidence and correlates of depression in Medicare beneficiaries with disabilities. We assessed the effect of HIV infection on developing depression in this population.

Design: We conducted a retrospective matched cohort study using a 5% sample of Medicare beneficiaries who qualified for disability coverage (1996-2015). Read More

View Article and Full-Text PDF

Sex differences in cytokine profiles during suppressive antiretroviral therapy.

AIDS 2022 May 24. Epub 2022 May 24.

Department of Medicine, University of California San Diego, La Jolla, CA.

Objective: Despite lower plasma HIV RNA levels, women progress faster to AIDS than men. The reasons for these differences are not clear but might be a consequence of an elevated inflammatory response in women.

Methods: We investigated sex differences in cytokine profiles by measuring the concentrations of 36 cytokine/chemokines by Luminex in blood of women and men (sex at birth) with chronic HIV infection under suppressive therapy. Read More

View Article and Full-Text PDF

Adverse perinatal outcomes associated with HAART and monotherapy: systematic review and meta-analysis.

AIDS 2022 May 24. Epub 2022 May 24.

National Perinatal Epidemiology Unit, Nuffield Department of Population Health.

Objectives: Assess adverse perinatal outcomes in women living with HIV (WLHIV) receiving HAART or zidovudine (ZDV) monotherapy, compared with antiretroviral therapy (ART)-naive WLHIV and HIV-negative women.

Design: Systematic review and meta-analysis.

Methods: We conducted a systematic literature review by searching PubMed, CINAHL, Global Health, and EMBASE for studies published during 1 January 1980 to 20 April 2020. Read More

View Article and Full-Text PDF

Years of life lost to cancer among the US HIV population, 2006-2015.

AIDS 2022 May 24. Epub 2022 May 24.

Infections and Immunoepidemiology Branch.

Objectives: We estimated years of life lost (YLLs) to all causes of death and YLL lost to cancer among persons with HIV (PWH) in the United States.

Design: Linked HIV and cancer registry data from the HIV/AIDS Cancer Match Study were used to identify incident cancers and deaths among PWH in 11 regions of the United States during 2006-2015.

Methods: Mean YLL (MYLL) to all causes of death and MYLL to cancer during 2006-2015 were derived from the restricted mean survival estimated from Cox proportional hazards regression models. Read More

View Article and Full-Text PDF

High incidence of subclinical peripheral artery disease in people with HIV.

AIDS 2022 May 24. Epub 2022 May 24.

Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet.

Objective: Atherosclerosis is common in people with HIV (PWH). Peripheral artery disease (PAD) is the peripheral manifestation of atherosclerosis, but little is known about the incidence of PAD in PWH. Our objective was to determine the PAD incidence in PWH and to investigate potential risk factors. Read More

View Article and Full-Text PDF

Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women.

AIDS 2022 May 17. Epub 2022 May 17.

The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.

Objective: To estimate the effect of intimate partner violence (IPV) on oral PrEP adherence among adolescent girls and young women (AGYW).

Design: We conducted a secondary analysis of data from HIV Prevention Trials Network 082 (HPTN 082), a multisite prospective study designed to assess oral PrEP adherence among AGYW in southern Africa.

Methods: We estimated the relative prevalence of high PrEP adherence 3 and 6 months after initiation among AGYW 16-25 years who reported a history of any IPV in the past year at enrollment versus AGYW who did not, both overall and by age. Read More

View Article and Full-Text PDF

Cytokines in HIV infection: authors' reply.

AIDS 2022 May;36(6):908-909

Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.

View Article and Full-Text PDF

Cytokines in HIV infection: different methods of assessment require different interpretations.

AIDS 2022 May;36(6):907-908

Research Laboratory, Division of Pediatric Infectious Diseases, Department of Pediatrics at Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.

View Article and Full-Text PDF

Urine tuberculosis diagnostics in patients with advanced HIV.

AIDS 2022 May;36(6):897-898

Institute for Global Health, University College London.

View Article and Full-Text PDF

Risk of subarachnoid haemorrhages and aneurysms in Danish People Living With HIV, a nationwide cohort study.

AIDS 2022 May 24. Epub 2022 May 24.

Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen.

Objective: It remains unclear whether people with HIV (PWH) have increased risk of aneurysms. We aimed to investigate if the risk of subarachnoid haemorrhage, cerebral aneurysm, aortic aneurysm and other arterial aneurysms and dissections is increased in PWH compared with the general population.

Design: We performed a nationwide population-based matched cohort study. Read More

View Article and Full-Text PDF

Abnormal cognitive aging in people with HIV: Evidence from Data Integration between two countries' cohort studies.

AIDS 2022 Apr 27. Epub 2022 Apr 27.

Departments of Neurology and HIV Medicine, St Vincent's Hospital and Peter Duncan Neurosciences Unit, St Vincent's Centre for Applied Medical Research.

Objectives: Previous research has shown inconsistent results on whether cognitive aging is abnormal in people with HIV (PWH) because of low sample size, cross-sectional design, and nonstandard neuropsychological methods. To address these issues, we integrated data from two longitudinal studies: Australian HIV and Brain Ageing Research Program (N = 102) and CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study (N = 924) and determined the effect of abnormal aging on neurocognitive impairment (NCI) among PWH.

Methods: Both studies used the same neuropsychological test battery. Read More

View Article and Full-Text PDF

High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.

AIDS 2022 Apr 23. Epub 2022 Apr 23.

Gilead Sciences Inc., Foster City, California, 94404 USA.

Objective: We investigated the prevalence of preexisting M184 V/I and associated risk factors among clinical trial participants with suppressed HIV and evaluated the impact of M184 V/I on virologic response after switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).

Design: Participant data were pooled from 6 clinical trials investigating the safety and efficacy of switching to B/F/TAF in virologically suppressed people with HIV.

Methods: Preexisting drug resistance was assessed by historical genotypes and/or baseline proviral DNA genotyping. Read More

View Article and Full-Text PDF

Surrogate neutralisation responses following SARS-CoV-2 vaccination in people living with HIV - comparison between inactivated and mRNA vaccine.

AIDS 2022 Apr 23. Epub 2022 Apr 23.

Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Objective: People living with HIV (PLHIV) co-infected with SARS-CoV-2 are at higher odds of severe diseases. Whereas the immunogenicity of mRNA vaccine and adenovirus-vectored vaccine was similar between PLHIV in stable condition and healthy adults, the effects of inactivated vaccines are not known.

Design: Prospective longitudinal observational study in real-world setting. Read More

View Article and Full-Text PDF

Significance of lymph node fine needle aspiration for the diagnosis of HIV-associated lymphoma in a low-resource setting.

AIDS 2022 Apr 23. Epub 2022 Apr 23.

Division of Anatomical Pathology, National Health Laboratory Service, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, SA.

Objective: Fine needle aspiration (FNA) is an early step in the work-up of lymphadenopathy in people living with HIV (PLWH). We set out to characterize the FNA cytology in PLWH and report on the time to lymphoma diagnosis through the FNA clinics in the public healthcare system in Johannesburg, South Africa.

Design: Retrospective review of laboratory database. Read More

View Article and Full-Text PDF

Coordination of inflammatory responses in children with perinatally-acquired HIV infection.

AIDS 2022 Apr 20. Epub 2022 Apr 20.

University of Colorado School of Medicine.

Objective: We investigated dynamics of inflammatory biomarkers in children with perinatally-acquired HIV (PHIV) who started antiretrovirals at age <3 years and achieved sustained virologic control (HIV plasma RNA<400 copies/mL).

Design: This was a retrospective analysis of inflammatory biomarkers in children enrolled in a randomized trial of early (<3 years of age) PI-based versus NNRTI-based regimens (P1060), who achieved sustained virologic control and participated in a neurodevelopmental follow-up study (P1104 s) between ages 5-11 years.

Methods: We measured 20 inflammatory biomarkers using ELISA or chemiluminescence at onset of sustained virologic control (Tc) and at P1104 s entry (Te). Read More

View Article and Full-Text PDF

Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy.

AIDS 2022 Apr 20. Epub 2022 Apr 20.

University of Paris and Hôpital Saint-Louis and Lariboisière, INSERM U944, Paris, France.

Objective: To assess the prevalence of CMV viremia in HIV-positive patients starting antiretroviral therapy (ART) and to evaluate its impact on clinical outcomes.

Design: Retrospective analysis of four clinical trials (INSIGHT FIRST, SMART, START, and ANRS REFLATE TB).

Methods: Stored plasma samples from participants were used to measure CMV viremia at baseline prior to initiating ART and at visits through one year of follow-up after ART initiation. Read More

View Article and Full-Text PDF

How informal healthcare providers improve uptake of HIV testing: qualitative results from a randomized controlled trial.

AIDS 2022 Apr 20. Epub 2022 Apr 20.

Department of Emergency Medicine, Weill Cornell Medicine, New York, USA.

Objective: Uganda is HIV-endemic with a prevalence of 5.7%. Lack of epidemic control has been attributed to low engagement with HIV testing. Read More

View Article and Full-Text PDF

Toward demystifying HIV as a risk factor for coronavirus disease 2019 complications.

AIDS 2022 04;36(5):749-750

Division of Infectious Diseases, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

View Article and Full-Text PDF

Proprotein convertase subtilisin/kexin type 9 inhibitors: a turning point in HIV-associated dyslipidemia?

AIDS 2022 04;36(5):745-747

Metabolic Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

View Article and Full-Text PDF

Coronavirus disease 2019 hospitalization outcomes in persons with and without HIV in Spain.

AIDS 2022 04;36(5):683-690

Internal Medicine Department, Gregorio Marañón General University Hospital, Madrid, Spain.

Objective: To compare coronavirus disease 2019 (COVID-19) hospitalization outcomes between persons with and without HIV.

Design: Retrospective observational cohort study in 150 hospitals in Spain.

Methods: Patients admitted from 1 March to 8 October 2020 with COVID-19 diagnosis confirmed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 positive) PCR test in respiratory tract samples. Read More

View Article and Full-Text PDF

Getting to the heart of the matter: the need for tailored cardiovascular prevention strategies in patients with HIV.

Authors:
Iulia Filip

AIDS 2022 04;36(5):N1-N3

MedEd Medical Communications, LLC, 23 Whiteoaks Circle, Bluffton, SC, USA.

View Article and Full-Text PDF